|
|
Exchange: |
American Stock Exchange |
Security
Type: |
Common |
Shares
Out: |
57,080,000 |
Market
Cap: |
151.26(M) |
Last
Volume: |
97,895 |
Avg
Vol: |
96,979 |
52
Week Range: |
$1.6 - $4.2 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drugs - Generic |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : 4.7 |
Insider 6 Months : 7.7 |
Insider 3/6 Months : 12.5 |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Galectin Therapeutics is a clinical stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease, cancer and selected other diseases. Co.'s main galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis and in clinical studies to decrease portal hypertension and prevent its complication: the development of esophageal varices. GR-MD-02 has the potential to treat various diseases due to galectin-3's involvement in multiple main biological pathways such as fibrosis, immune cell function and immunity, cell differentiation, cell growth, and apoptosis (cell death).
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
3,900 |
10,900 |
11,800 |
30,698 |
Total Buy Value |
$9,006 |
$29,316 |
$31,165 |
$57,953 |
Total People Bought |
2 |
4 |
4 |
5 |
Total Buy Transactions |
4 |
8 |
10 |
16 |
Total Shares Sold |
0 |
25,000 |
25,000 |
25,000 |
Total Sell Value |
$0 |
$76,500 |
$76,500 |
$76,500 |
Total People Sold |
0 |
1 |
1 |
1 |
Total Sell Transactions |
0 |
2 |
2 |
2 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Shlevin Harold H. |
Chief Executive Officer |
|
2019-06-04 |
4 |
OE |
$1.37 |
$11,927 |
D/D |
8,706 |
8,706 |
|
- |
|
Uihlein Richard E |
Director |
|
2019-05-31 |
4 |
B |
$4.28 |
$32,999 |
I/I |
7,710 |
27,710 |
2.25 |
- |
|
Uihlein Richard E |
Director |
|
2019-05-31 |
4 |
B |
$4.28 |
$19,999,995 |
D/D |
4,672,896 |
7,801,385 |
3.92 |
- |
|
Uihlein Richard E |
Director |
|
2019-05-31 |
4/A |
B |
$4.28 |
$32,999 |
I/I |
7,710 |
27,710 |
2.25 |
- |
|
Uihlein Richard E |
Director |
|
2019-05-31 |
4/A |
B |
$4.28 |
$19,999,995 |
D/D |
4,672,896 |
7,801,385 |
3.92 |
- |
|
Lewis Joel |
Director |
|
2019-05-31 |
4 |
B |
$4.28 |
$54,994 |
D/D |
12,849 |
78,649 |
2.39 |
- |
|
Omenn Gilbert S |
Director |
|
2019-05-31 |
4 |
B |
$4.28 |
$79,514 |
D/D |
18,578 |
66,769 |
2.39 |
- |
|
Callicutt Jack W |
Chief Financial Officer |
|
2019-05-31 |
4 |
B |
$4.28 |
$10,075 |
D/D |
2,354 |
3,614 |
2.74 |
- |
|
Freeman Kevin D |
Director |
|
2019-05-31 |
4 |
B |
$4.28 |
$6,103 |
D/D |
1,426 |
23,469 |
2.39 |
- |
|
Freeman Kevin D |
Director |
|
2019-05-31 |
4 |
B |
$4.28 |
$32,999 |
I/I |
7,710 |
9,710 |
2.1 |
- |
|
Eldred Kary |
Director |
|
2019-05-31 |
4 |
B |
$4.28 |
$12,981 |
D/D |
3,033 |
44,415 |
2.39 |
- |
|
Uihlein Richard E |
Director |
|
2019-05-29 |
4 |
OE |
$5.00 |
$2,500,000 |
D/D |
500,000 |
3,128,489 |
|
- |
|
Uihlein Richard E |
Director |
|
2019-05-29 |
4/A |
OE |
$5.00 |
$2,500,000 |
D/D |
500,000 |
3,128,489 |
|
- |
|
Czirr James C |
Managing Member of GP |
|
2019-05-03 |
4 |
D |
$0.00 |
$0 |
D/D |
(67,515) |
6,441,786 |
|
- |
|
Uihlein Richard E |
Director |
|
2019-04-09 |
4 |
B |
$4.82 |
$99,851 |
D/D |
20,700 |
2,628,489 |
3.92 |
- |
|
Lewis Joel |
Director |
|
2019-04-05 |
4 |
B |
$4.82 |
$3,214 |
D/D |
667 |
65,800 |
2.31 |
- |
|
Uihlein Richard E |
Director |
|
2019-04-05 |
4 |
B |
$4.81 |
$100,972 |
D/D |
21,000 |
2,607,789 |
3.92 |
- |
|
Freeman Kevin D |
Director |
|
2019-04-05 |
4 |
B |
$4.73 |
$2,365 |
I/I |
500 |
2,000 |
2.02 |
- |
|
Rubin Marc |
Director |
|
2019-02-22 |
4 |
AS |
$6.02 |
$5,175 |
D/D |
(859) |
13,581 |
|
- |
|
Rubin Marc |
Director |
|
2019-02-22 |
4 |
OE |
$2.39 |
$2,053 |
D/D |
859 |
14,440 |
|
- |
|
Rubin Marc |
Director |
|
2019-02-21 |
4 |
AS |
$6.00 |
$303,026 |
D/D |
(50,326) |
13,581 |
|
- |
|
Rubin Marc |
Director |
|
2019-02-21 |
4 |
OE |
$2.39 |
$103,549 |
D/D |
43,326 |
56,907 |
|
- |
|
Freeman Kevin D |
Director |
|
2019-02-08 |
4 |
B |
$4.29 |
$6,428 |
I/I |
1,500 |
1,500 |
2.1 |
- |
|
Lewis Joel |
Director |
|
2019-02-07 |
4 |
B |
$4.48 |
$4,484 |
D/D |
1,000 |
65,133 |
2.31 |
- |
|
Amelio Gilbert F |
Director |
|
2019-01-31 |
4 |
S |
$5.00 |
$65,235 |
D/D |
(13,047) |
154,614 |
|
- |
|
320 Records found
|
|
Page 7 of 13 |
|
|